How Two Immunology Teams Made Headlines

“Human Immune Defenses Are Transplanted in Mice” beckoned the headline on a front page of the New York Times last month. It announced a story arousing high expectations for a powerful new medical research tool Independently, two teams of researchers had shown that rodents having no immune systems of their own could be made to serve as true models of the human immune system, and this promised to open many doors in the study of human disease—offering insights into some cancers, f

Written byLaurel Joyce
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

“Human Immune Defenses Are Transplanted in Mice” beckoned the headline on a front page of the New York Times last month. It announced a story arousing high expectations for a powerful new medical research tool Independently, two teams of researchers had shown that rodents having no immune systems of their own could be made to serve as true models of the human immune system, and this promised to open many doors in the study of human disease—offering insights into some cancers, for example, and AIDS.

But of the scientists themselves and of the secrets to their success, the Times said little. Who were they, and exactly how did they achieve what no scientists before them had ever done? Beginning on page 24, The Scientist takes a close look at them.

The excitement engendered by their achievements spurred a number of major newspapers in addition to the Times to run prominent ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies